Thursday 24 June

Friday 25 June

Session 1: HCV replication dynamics and pathogenesis

Invited lecture: The chimpanzee model of HCV and preclinical antiviral testing

R. Lanford

Pres.

Discovery of novel, potent NS5A inhibitors with favorable pharmacokinetics and robust activity in an HCV animal model

B. Buckman

N.A.

Preclinical characteristics and microdosing pharmacokinetics support low-dose, once-daily dosing of the HCV NS3/4A protease inhibitor ITMN-8187

R. Rajagopalan

N.A.

Fidelity of HCV NS5B and implications for the development of drug resistance

M. Gotte

N.A.

Resistance mutations to different classes of HCV-specific inhibitors reduce fitness by different mechanisms

K. Ritola

Pres.

Session 2: Clinical relevance and management of HCV drug resistance

Invited lecture: Drug resistance to HCV DAAs: Impact on HCV therapies

I. Najera

N.A.

Invited lecture: Future treatment options for current non-responders

M. Fried

N.A.

Characterization of resistant variants in treatment-naive and experienced genotype 1 HCV patients in phase 2 trials of Telaprevir/Peg-IFN/RBV

T. Kieffer

N.A.

Peptidomimetic escape mechanisms due to genetic diversity in the ligand-binding site of the HCV NS3/4A serine protease

C. Welsch

N.A.

BI 201335, a potent HCV NS3 protease inhibitor in chronic genotype-1 infection: genotypic and phenotypic analysis of the NS3 protease domain

G. Kukolj

N.A.

Long-term follow-up of patients treated with boceprevir + peg-intron/ribavirin: durability of response and rate of reversion of resistance mutations

R. Ralston

N.A.